Pretriscuspid shunt and Eisenmenger syndrome: a deadly combination
| Autor: | M Lopez Ramon, L Molina Ferragut, J.A. Barberà Mir, M Lazaro Salvador, J Playan Escribano, R Lopez Reyes, L Dos Subira, E Martinez-Quintana, Suberviola, I. Otero González, A Martinez Menaca, Rehap investigators Rehiped investigators, E Barrios Garrido-Lestache, Elvira Barrios Garrido-Lestache, P Escribano Subias, T Segura De La Cal |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.disease Comorbidity Shunt (medical) medicine.anatomical_structure New York Heart Association Classification Eisenmenger syndrome Internal medicine Epidemiology medicine Vascular resistance Cardiology Eisenmenger Complex Cardiology and Cardiovascular Medicine business |
| Zdroj: | European Heart Journal. 41 |
| ISSN: | 1522-9645 0195-668X |
| Popis: | Introduction Pulmonary arterial hypertension (PAH) is a common comorbidity in congenital heart disease (CHD) and significantly affects prognosis. Our aim was to investigate how the location of the shunt influences the outcome of these patients. Methods The REHAP registry is a Spanish multicentre voluntary registry of patients over 14 years of age, which includes patients with congenital heart disease and PAH, starting in 2007. Baseline characteristics, functional class, right catheterization data, treatment and survival were compared. We performed a cox regression model for assessing the impact of the type of shunt on prognosis, after looking for confusing and effect modifying variables. Results 664 patients were analyzed, their characteristics are detailed in the table. Mean follow up time was 10 years. We performed a survival analysis adjusted for the confounding variables: age (Hazard ratio (HR) 1.02 p Conclusion The type of shunt significantly affects prognosis in Eisenmenger patients, with a much worse outcome for those with pretricuspid shunts. Functional class and clinical group are also closely related to outcome. Funding Acknowledgement Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): MSD, GSK |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|